3,719 results on '"Merseburger AS"'
Search Results
52. Kardiovaskuläre Komplikationen unter Androgenentzugstherapie: Vorteil für Gonadotropin-Releasing-Hormon-Antagonisten? Ein Update
53. Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians
54. Metastatic Surgery in Advanced Renal Cell Carcinoma
55. Surgical Methods in Treatment of Kidney Tumors: Open Surgery Versus Laparoscopy Versus Robotic Surgery
56. Partial Versus Total Nephrectomy: Indications, Limitations, and Advantages
57. Prognostic and Predictive Markers, and Stratifications Tables, for the Detection and Treatment of Renal Cell Carcinoma
58. Advisable Follow-Up for Kidney Tumors
59. Treatment of Small Renal Masses
60. Systemic and Sequential Therapy in Advanced Renal Cell Carcinoma
61. Epidemiology of Renal Cell Carcinoma and Its Predisposing Risk Factors
62. Molecular Heterogeneity of Renal Cell Carcinoma
63. Symptoms of Kidney Cancer and Appropriate Diagnostic Tools
64. Histological (Sub)Classifications and Their Prognostic Impact in Renal Cell Carcinoma
65. Clinical Aspects and Investigations in Genitourinary Cancer
66. Clinical Trials and Their Principles in Urologic Oncology
67. Bone Target Therapy in Urologic Malignancies
68. Molecular Basics on Genitourinary Malignancies
69. Medikamentöse Therapie des metastasierten Nierenzellkarzinoms
70. Klinik
71. New computed tomographic predictors of complicated perioperative course of 17.5F mini-percutaneous nephrolithotomy (mini-PNL)
72. Aktuelle Therapie des metastasierten Prostatakarzinoms
73. Large Language Modelle zur schnellen Vereinfachung der Eingabe von Qualitätssicherungsdaten: Performance-Test mit Echtdaten am Beispiel der Tumordokumentation in der Urologie.
74. Surveillance of non‐muscle‐invasive bladder cancer with blue‐light cystoscopy: a meta‐analysis.
75. Aktuelle Ambulantisierungspotenziale in der Urologie - was bedeutet das IGES Gutachten auf Echtdaten angewendet.
76. Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study
77. MP14-08 REAL-WORD CLINICAL CHARACTERIZATION OF METASTATIC HORMONE SENSITIVE PROSTATE CANCER: DATA FROM THE EUROPEAN NETWORK OF EXCELLENCE FOR BIG DATA IN PROSTATE CANCER (PIONEER)
78. Therapy Optimization in the Management of Metastatic Hormone-sensitive Prostate Cancer: Insights from the ARASENS Study
79. MP14-09 DEVELOPMENT OF A PREDICTION MODEL OF SURVIVAL AMONGST PATIENTS WITH METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC) USING BIG DATA: INTERIM RESULTS FROM THE EUROPEAN NETWORK OF EXCELLENCE FOR BIG DATA IN PROSTATE CANCER (PIONEER)
80. Large Language Modelle zur schnellen Vereinfachung der Eingabe von Qualitätssicherungsdaten: Performance-Test mit Echtdaten am Beispiel der Tumordokumentation in der Urologie
81. Effects of hyperthermia on cisplatin tissue penetration and gene expression in peritoneal metastases: results from a randomized trial in ovarian cancer
82. Breaking boundaries: Exploring extended pembrolizumab in first-line treatment of renal cell carcinoma with axitinib-pembrolizumab combination
83. SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette–Guérin in patients with BCG-naive high-risk non–muscle-invasive bladder cancer
84. Development of a predictive model for death amongst patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) treated with one of the approved treatment plans, on characteristics present at admission using Big data: Preliminary results from the European network of excellence for big data in prostate cancer (PIONEER)
85. Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts
86. Im Fokus: Das Urothelkarzinom: Die wichtigsten Studienergebnisse der vergangenen Monate auf einen Blick
87. Sekundärprävention des nichtmuskelinvasiven Blasenkarzinoms (NMIBC)
88. COCONUT online: Collection of Open Natural Products database
89. Phase-III-Wirksamkeitsstudie zur intravesikalen Instillation von Mistelextrakt bei oberflächlichem Blasenkarzinom (TIM): Studie zur Therapie beim nichtmuskelinvasiven Harnblasenkarzinom – AB 40/11 der AUO
90. Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel
91. Hemopatch® as a Hemostatic Agent is Safe in Partial Nephrectomy: A Large, Single-Surgeon Retrospective Evaluation
92. Bicentric Retrospective Analysis of en Bloc Resection and Muscularis Mucosae Detection Rate in Non-Muscle Invasive Bladder Tumors: A Real-World Scenario
93. Forschungsaktivitäten zum Peniskarzinom in Deutschland und Österreich - eine Fragebogenstudie unter Lehrstuhlinhabern mit ergänzender Literaturrecherche und bibliometrischer Analyse
94. Studie zum abgestuften immuntherapeutischen Ansatz bei fortgeschrittenem oder metastasiertem Transitionalzellkarzinom: Einarmige klinische Prüfung (Phase II; TITAN TCC) – AB 57/17 der AUO
95. Adherence to the EAU Guideline Recommendations for Local Tumor Treatment in Penile Cancer: Results of the European PROspective Penile Cancer Study Group Survey (E-PROPS)
96. Therapie des metastasierten Urothelkarzinoms
97. Laser fibre, rather than the stone, may harm the scope: retrospective monocentric analysis of 26 pre- and intraoperative factors of flexible ureteroscope (fURS) damage
98. Therapie des metastasierten kastrationsresistenten Prostatakarzinoms
99. Befundbericht zu Prostatastanzbiopsien – was Pathologen liefern und Urologen wollen
100. The new ISUP 2014/WHO 2016 prostate cancer grade group system: first résumé 5 years after introduction and systemic review of the literature
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.